Another controversy is brewing due to the opacity surrounding the regulatory approval granted to Favipiravir for the treatment of COVID-19 patients with mild or moderate symptoms. No scientific consensusThe Drugs Controller General of India (DCGI) has approved Glenmark Pharmaceuticals, an Indian pharmaceutical company, to sell generic versions of Favipiravir for the treatment of COVID-19. There is no information on the DCGI’s website explaining the scientific basis of its approval of Favipiravir for COVID-19. With regard to Favipiravir, we know that Glenmark was conducting a clinical trial for this drug in India. We are unable to find well-designed robust scientific studies on the effectiveness and safety of this drug in COVID-19 patients.

Source: The Hindu June 24, 2020 18:46 UTC